A large institutional investment firm engaged Shift Health to evaluate the products in a portfolio of pharma royalties it had an opportunity to acquire.
A US-based biotech company required support to identify, evaluate and prioritize novel immunotherapies and targeted oncology drug candidates to supplement its clinical pipeline.
An Asian specialty healthcare company needed to assess the US market for novel image guidance medical device systems for minimally invasive cardiac interventions.
A top-5 global biopharmaceutical company wanted to identify promising oncology drug candidates that it could in-license or acquire to bolster its oncology franchise revenues over the near term.
Shift Health was engaged by a leading US investment firm to evaluate an asset and project sales in order to inform their decision to invest in an established biotechnology company expanding into new markets.